

University of Groningen

Targeting NF- κ B signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis

Merino-Vico, Ana; van Hamburg, Jan Piet; Tuijnenburg, Paul; Frazzei, Giulia; Al-Soudi, Aram; Bonasia, Carlo G; Helder, Boy; Rutgers, Abraham; Abdulahad, Wayel H; Stegeman, Coen A

Published in:
Journal of Autoimmunity

DOI:
[10.1016/j.jaut.2023.103133](https://doi.org/10.1016/j.jaut.2023.103133)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2024

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Merino-Vico, A., van Hamburg, J. P., Tuijnenburg, P., Frazzei, G., Al-Soudi, A., Bonasia, C. G., Helder, B., Rutgers, A., Abdulahad, W. H., Stegeman, C. A., Sanders, J.-S., Bergamaschi, L., Lyons, P. A., Bijma, T., van Keep, L., Wesenhagen, K., Jongejan, A., Olsson, H., de Vries, N., ... Tas, S. W. (2024). Targeting NF- κ B signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis. *Journal of Autoimmunity*, 142, Article 103133. <https://doi.org/10.1016/j.jaut.2023.103133>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Letters


RESEARCH LETTER

Health-Related Quality of Life in Solid Organ Transplant Recipients With vs Without Keratinocyte Carcinoma

Keratinocyte carcinoma (KC) is the most common malignant disease in solid organ transplant recipients, but we know little about its association with overall (generic) health-related quality of life (HRQoL) and KC-specific HRQoL in solid organ transplant recipients.^{1,2} Although previous research showed that sun-protective behavior increases after KC treatment,³ this topic is not addressed by KC-specific HRQoL questionnaires.⁴ The recently developed Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) questionnaire does assess the association of behavior changes with HRQoL.⁵ In this study, we compared generic HRQoL between solid organ transplant recipients with and without KC and explored variables associated with KC-specific HRQoL in solid organ transplant recipients using the BaSQoL.

Methods | In this cross-sectional study, data of the TransplantLines study was used (NCT03272841).⁶ Overall, 1119 solid organ transplant recipients included between June 2015 and February 2019, at 1 year or more after transplantation, were considered potentially eligible (Figure). Of those, there were 180 participants who indicated prior skin cancer, and medical record review identified 106 cases with histologically confirmed KC; 74 solid organ transplant recipients without histologically confirmed KC diagnosis were excluded. Of the 106 solid organ transplant recipients with histologically confirmed KC, 9 were excluded (n = 5 melanoma; n = 4 deceased) from further filling out the BaSQoL questionnaire. The 939 solid organ transplant recipients who indicated they were never diagnosed with skin cancer served as controls. The study was approved by the University Medical Center Groningen institutional review board and all participants provided written informed consent. Generic HRQoL was measured using the Physical and Mental Component Scale (PCS, MCS) of the Short Form 36 (SF-36) Health Survey (Supplement), where higher scores indicate better perceived HRQoL. Disease-specific HRQoL was measured using the BaSQoL, a 16-item KC-specific HRQoL instrument comprising 5 subscales.⁵ Higher BaSQoL subscale scores indicate worse perceived KC-specific HRQoL. Mann-Whitney *U* tests were used to compare SF-36 scores between solid organ transplant recipients with and without KC. Log transformation was applied to the number of KCs before statistical analyses. The effect of age, sex, type of transplantation, number of KCs and time after transplantation on BaSQoL subscale scores was examined by multivariable linear regression analyses. No mathematical correction of multiple comparisons has been performed. Statistical analyses were performed using SPSS statistical software (version 23.0, IBM) and *P* value was set at <.05, 2 sided.

Figure. Study Flowchart



SOTR indicates solid organ transplant recipient; KC, keratinocyte carcinoma.

Data analyses were performed between April 11, 2019, and June 29, 2019.

Results | All included solid organ transplant recipients (94 with prior KC, 939 without KC) filled out the SF-36 questionnaire and all solid organ transplant recipients with prior KC also filled out the BaSQoL questionnaire; those solid organ transplant recipients with KC filled out the SF-36 questionnaire after KC diagnosis. Demographic data, clinical variables, and raw questionnaire scores are shown in the Table. The solid organ transplant recipients with KC were significantly older, had a longer time since transplantation, and were more often retired. There were no significant differences in generic HRQoL scores between solid organ transplant recipients with and without KC (Table). Multivariable analysis showed that having a higher number of KCs was independently associated with worse KC-specific HRQoL on the appearance (β , 0.64; 95% CI, 0.31-0.96; $P < .001$) and behavior (β , 0.60; 95% CI, 0.25-0.94; $P < .001$) subscales. Being female showed an independent association with worse KC-specific HRQoL on the appearance subscale (β , 0.29; 95% CI, 0.04-0.54; $P = .03$).

Discussion | Solid organ transplant recipients with and without KC did not differ in their generic HRQoL. However, when

Table. Cohort Characteristics and Raw Questionnaire Scores

Variable	Study Group	Control Group	P Value
	SOTRs With Prior KC (n = 94)	SOTRs Without KC (n = 939)	
Age, mean (SD), y	67.0 (7.4)	54.5 (13.6)	<.001 ^a
Sex, No. (%)			
Male	49 (52.1)	530 (56.4)	.45 ^b
Solid organ transplant type, No. (%)			
Kidney	53 (56.4)	523 (55.7)	
Liver	23 (24.5)	238 (25.3)	.99 ^c
Heart/lung	18 (19.1)	178 (19.0)	
Time after OT, median (IQR), y	15.9 (9.3-23.2)	6.2 (2.4-13.0)	<.001 ^d
Employment status, No. (%)			
Employed	11 (11.7)	338 (36.0)	
Retired	55 (58.5)	230 (24.5)	
Incapacitated	11 (11.7)	240 (25.6)	<.001 ^c
Other ^e	9 (9.6)	122 (13.0)	
Unknown	8 (8.5)	9 (1.0)	
Type and No. of KC per patient, No. (%)			
Basal cell carcinoma			
Yes	60 (63.8)	NA	
Single	25 (26.6)	NA	
Multiple	35 (37.2)	NA	
Range	1-53	NA	
Squamous cell carcinoma			
Yes	55 (58.5)	NA	
Single	24 (25.5)	NA	
Multiple	31 (33.0)	NA	
Range	1-61	NA	
Total KC lesions per patient, median (IQR), range	2 (1-5), 1-62	NA	
Questionnaire			
SF-36, median (IQR)			
PCS	71.9 (49.8-83.4)	75.7 (58.7-86.3)	.07 ^d
MCS	80.0 (65.3-88.0)	81.6 (67.7-89.8)	.29 ^d
BaSQoL ^f median (IQR)			
BH (range 0-3)	.75 (.25-1.50)	NA	
DT (range 0-3)	.67 (.33-1.08)	NA	
WS (range 0-3)	.75 (.25-1.06)	NA	
AP (range 0-3)	.33 (0-1.00)	NA	
OP (range 0-3)	.50 (0-1.00)	NA	

Abbreviations; AP, appearance; BaSQoL, Basal and Squamous Cell Carcinoma Quality of Life; BH, behavior; DT, diagnosis and treatment; IQR, interquartile range; KC, keratinocyte carcinoma; MCS, mental component scale; NA, not applicable; OP, other people; OT, organ transplantation; PCS, Physical Component Scale; SF-36, Short Form 36; SOTRs, solid organ transplant recipients; WS, worries.

^a Student *t* test.

^b χ^2 test.

^c Fisher-Freeman-Halton test.

^d Mann-Whitney *U* test.

^e Student, housekeeping, or unemployed.

^f Cronbach α values were 0.86, 0.80, 0.83, 0.86, and 0.76, respectively.

assessed with a KC-specific HRQoL instrument (BaSQoL), differences were noted. Among solid organ transplant recipients with a prior KC, more KCs were associated with reductions in HRQoL related to sun-protective behavior and appearance, and women had worse HRQoL related to appearance than men. Use of KC-specific HRQoL instruments in solid organ transplant recipients may identify changes that are not apparent with instruments designed to assess overall HRQoL and may allow targeted counseling for those at higher risk of impaired HRQoL.

Misclassification regarding KC status of our control group may have occurred unintentionally due to recall bias. However, we believe that it is unlikely that KC significantly impairs HRQoL in those who reported they were never diagnosed with KC.

Melvin Frie, BSc
Coby Annema, PhD
Emily S. X. Knijff, BSc
Stephan J. L. Bakker, MD, PhD
Adelita V. Ranchor, PhD
Michele F. Eisenga, MD, PhD
Emöke Rácz, MD, PhD

Author Affiliations: Department of Dermatology; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Frie, Rácz); Section of Nursing Research, Department of Health Sciences; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Annema); Division of Nephrology, Department of Internal Medicine; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Knijff, Bakker, Eisenga); Department of Health Psychology; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Ranchor).

Corresponding Author: Melvin Frie, BSc, Department of Dermatology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, the Netherlands (m.frie@umcg.nl).

Accepted for Publication: November 27, 2019.

Published Online: January 30, 2020. doi:10.1001/jamadermatol.2019.4541

Author Contributions: Dr Rácz and Mr Frie had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Mr Frie and Dr Annema contributed equally to the work.

Study concept and design: Frie, Annema, Bakker, Ranchor, Racz.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Frie, Annema, Knijff, Ranchor, Eisenga, Racz.

Critical revision of the manuscript for important intellectual content: Frie, Annema, Bakker, Ranchor, Eisenga, Racz.

Statistical analysis: Frie, Annema, Eisenga, Racz.

Obtained funding: Bakker.

Administrative, technical, or material support: Knijff, Racz.

Study supervision: Bakker, Eisenga, Racz.

Conflict of Interest Disclosures: Dr Eisenga reported personal fees from Vifor Pharma outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by a grant from Astellas BV.

Role of the Funder/Sponsor: Astellas BV had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Meeting Presentation: This study was presented at the 21st Annual Meeting of the Dutch Society for Experimental Dermatology; January 30, 2019; Lunteren,

the Netherlands and the Skin Care in Organ Transplant Patients Europe (SCOPE) 19th Annual Meeting; September 27, 2019; Barcelona, Spain.

1. O'Reilly F, Traywick C, Pennie ML, Foster JK, Chen SC. Baseline quality of life and anxiety in solid organ transplant recipients: a pilot study. *Dermatol Surg*. 2006;32(12):1480-1485. doi:10.1111/j.1524-4725.2006.32356.x

2. Moloney FJ, Keane S, O'Kelly P, Conlon PJ, Murphy GM. The impact of skin disease following renal transplantation on quality of life. *Br J Dermatol*. 2005; 153(3):574-578. doi:10.1111/j.1365-2133.2005.06699.x

3. Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB. Quality of life and sun-protective behavior in patients with skin cancer. *Arch Otolaryngol Head Neck Surg*. 2004;130(2):141-146. doi:10.1001/archotol.130.2.141

4. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. *J Am Acad Dermatol*. 2013;69(2):e59-e67. doi:10.1016/j.jaad.2012.09.017

5. Waalboer-Spuij R, Hollestein LM, Timman R, van de Poll-Franse LV, Nijsten TE. Development and validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire. *Acta Derm Venereol*. 2018; 98(2):234-239. doi:10.2340/00015555-2806

6. Eisenga MF, Gomes-Neto AW, van Londen M, et al. Rationale and design of TransplantLines: a prospective cohort study and biobank of solid organ transplant recipients. *BMJ Open*. 2018;8(12):e024502. doi:10.1136/bmjopen-2018-024502